Onconova Therapeutics Inc (ONTX) Receives $8.00 Consensus Price Target from Brokerages

Onconova Therapeutics Inc (NASDAQ:ONTX) has been assigned an average recommendation of “Hold” from the six ratings firms that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating and four have given a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $7.33.

Several brokerages recently weighed in on ONTX. HC Wainwright set a $6.00 price target on shares of Onconova Therapeutics and gave the company a “buy” rating in a research report on Tuesday. Zacks Investment Research downgraded shares of Onconova Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday. Maxim Group set a $6.00 price target on shares of Onconova Therapeutics and gave the company a “buy” rating in a research report on Thursday, November 9th. Finally, ValuEngine raised shares of Onconova Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st.

Large investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its position in Onconova Therapeutics by 58.4% in the 2nd quarter. Vanguard Group Inc. now owns 87,940 shares of the biopharmaceutical company’s stock worth $190,000 after purchasing an additional 32,418 shares during the period. 683 Capital Management LLC grew its position in Onconova Therapeutics by 21.0% in the 3rd quarter. 683 Capital Management LLC now owns 375,000 shares of the biopharmaceutical company’s stock worth $641,000 after purchasing an additional 65,140 shares during the period. Sabby Management LLC grew its position in Onconova Therapeutics by 104.0% in the 2nd quarter. Sabby Management LLC now owns 784,000 shares of the biopharmaceutical company’s stock worth $1,693,000 after purchasing an additional 399,640 shares during the period. Finally, Tyndall Capital Partners L P grew its position in Onconova Therapeutics by 91.4% in the 2nd quarter. Tyndall Capital Partners L P now owns 997,022 shares of the biopharmaceutical company’s stock worth $2,154,000 after purchasing an additional 476,190 shares during the period. 25.44% of the stock is owned by institutional investors and hedge funds.

Shares of Onconova Therapeutics (ONTX) traded down $0.01 on Tuesday, hitting $1.38. 265,983 shares of the company traded hands, compared to its average volume of 130,996. Onconova Therapeutics has a 12 month low of $1.21 and a 12 month high of $3.88.

Onconova Therapeutics (NASDAQ:ONTX) last announced its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.73) by $0.02. The company had revenue of $0.11 million during the quarter, compared to the consensus estimate of $0.29 million. Onconova Therapeutics had a negative net margin of 2,855.94% and a negative return on equity of 558.97%. research analysts forecast that Onconova Therapeutics will post -2.82 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://ledgergazette.com/2017/12/15/onconova-therapeutics-inc-ontx-receives-8-00-consensus-price-target-from-brokerages.html.

About Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.

Receive News & Ratings for Onconova Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply